Indisulam synergizes with melphalan to inhibit Multiple Myeloma malignancy via targeting TOP2A.
Multiple myeloma (MM) is the second most prevalent hematologic malignancy which remains uncurable. Numerous drugs have been discovered to inhibit MM cells. Indisulam, an aryl sulfonamide, has a potent anti-myeloma activity in vitro and in vivo. This study aims to explore the new mechanism of indisul...
Saved in:
Main Authors: | Chengyu Wu, Chao Wu, Jia Liu, Mingyuan Jia, Xinyi Zeng, Ze Fu, Ziqi He, Wenbin Xu, Hua Yan |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2024-01-01
|
Series: | PLoS ONE |
Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0299019&type=printable |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bortezomib (velcade) plus melphalan and prednisone in elderly untreated patients with multiple myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01) -
Repeated use of hybrid isolated chemoperfusion with melphalan in non-resectable liver malignancy
by: A. I. Babich, et al.
Published: (2024-03-01) -
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial
by: Sara Bringhen, et al.
Published: (2025-07-01) -
Pharmacokinetics and outcome of high-dose melphalan followed by autologous stem cell transplantation in dialysis-dependent patients with multiple myeloma
by: Rabea Mecklenbrauck, et al.
Published: (2025-01-01) -
Synergism and synergic effects in polymer`s processing technology
by: Yu. A. Naumova
Published: (2013-06-01)